Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 16/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429908 | 1.00 | WDR5 (1.00) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL24429903 | 0.89 | WDR5 (0.80) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL29891301 | 0.89 | WDR5 (0.80) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL29891078 | 0.83 | WDR5 (1.00) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL24429902 | 0.83 | WDR5 (1.00) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL24429895 | 0.78 | WDR5 (1.00) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL29544541 | 0.78 | WDR5 (1.00) | WDR5KMT2AALDH1A1CYP2D6GAA | |
| SCHEMBL24429879 | 0.77 | WDR5 (1.00) | WDR5KMT2A | |
| SCHEMBL29544609 | 0.77 | WDR5 (1.00) | WDR5KMT2A | |
| SCHEMBL24429916 | 0.76 | WDR5 (0.62) | WDR5KMT2AALDH1A1CYP2D6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-10-28 | — | — | US | disclosed |
| CN-109734674-B | Aniline WDR5 protein-protein interaction inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-26 | — | — | CN | disclosed |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | MLLT1, WDR77, MLLT3 | WDR5 4/4885KMT2A 38/4885ALDH1A1 2270/4885 |
| US-20220152027-A1 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | MLLT1, WDR77, MLLT3 | WDR5 4/4885KMT2A 38/4885ALDH1A1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.